A Phase II, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-dose Study to Investigate the Safety and Efficacy of 3-month AD17002 Treatment in Adults With Inadequately Controlled Moderate to Severe Eosinophilic Asthma
Latest Information Update: 03 Dec 2025
At a glance
- Drugs AD 17002 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Advagene Biopharma
Most Recent Events
- 03 Dec 2025 New trial record